|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
AngioChem Granted U.S. Patent for Transporting Drug Compounds across the Blood-Brain Barrier, Using Novel EPiC Technology
3/14/2011 9:22:05 AM
MONTREAL--(BUSINESS WIRE)--Angiochem, Inc., a clinical stage biotechnology company, today announced that its second patent has been granted by the U.S. Patent and Trademark office. Patent number 7,902,156, is entitled “Aprotinin Polypeptides for Transporting a Compound Across the Blood-Brain Barrier”. This key patent covers the transport of drug compounds derived from Angiochem’s Engineered Peptide Compound (EPiC) technology, including compounds that contain small molecules, peptides and proteins. EPiC drugs have the potential to efficiently and effectively cross the blood-brain barrier (BBB) to treat a wide range of brain diseases and brain-related disorders, many of which represent unmet medical needs including brain cancers, pain management, diabetes, obesity and neurological disorders such as Parkinson’s disease.
|
|
|
|
|
|
|
|
|
|
|